Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Martin Sattler, Rifat Hasina, Mamatha M. Reddy, et al.
Therapeutic Advances in Medical Oncology (2011) Vol. 3, Iss. 4, pp. 171-184
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Bryan Chan, Brett Hughes
PubMed (2015) Vol. 4, Iss. 1, pp. 36-54
Closed Access | Times Cited: 678
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Andō, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3491-3491
Open Access | Times Cited: 241
Molecular pathways and therapeutic targets in lung cancer
Emma Shtivelman, Thomas A. Hensing, George R. Simon, et al.
Oncotarget (2014) Vol. 5, Iss. 6, pp. 1392-1433
Open Access | Times Cited: 199
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
Sibi Raj, Kavindra Kumar Kesari, Arun Kumar, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 96
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
The emerging role of MET/HGF inhibitors in oncology
Giorgio V. Scagliotti, Silvia Novello, Joachim von Pawel
Cancer Treatment Reviews (2013) Vol. 39, Iss. 7, pp. 793-801
Closed Access | Times Cited: 192
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
Yuxin Lin, Xian Wang, Hongchuan Jin
PubMed (2014) Vol. 4, Iss. 5, pp. 411-35
Closed Access | Times Cited: 166
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan, Victoria L. Peek, Rose T. Ajamie, et al.
Investigational New Drugs (2012) Vol. 31, Iss. 4, pp. 833-844
Open Access | Times Cited: 152
Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions
Sanaullah Sajib, Fatema Tuz Zahra, Michail S. Lionakis, et al.
Angiogenesis (2017) Vol. 21, Iss. 1, pp. 1-14
Closed Access | Times Cited: 131
Papillary renal cell carcinoma: A review of the current therapeutic landscape
Giulia Courthod, Marcello Tucci, Massimo Di Maïo, et al.
Critical Reviews in Oncology/Hematology (2015) Vol. 96, Iss. 1, pp. 100-112
Open Access | Times Cited: 121
A Novel Classification of Lung Cancer into Molecular Subtypes
Lisandra West, Smruti J. Vidwans, Nicholas Campbell, et al.
PLoS ONE (2012) Vol. 7, Iss. 2, pp. e31906-e31906
Open Access | Times Cited: 119
The Evolution of Therapies in Non-Small Cell Lung Cancer
Vishal Boolell, Muhammad Alamgeer, D. Neil Watkins, et al.
Cancers (2015) Vol. 7, Iss. 3, pp. 1815-1846
Open Access | Times Cited: 116
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Pascale Tomasini, Preet Walia, Catherine Labbé, et al.
The Oncologist (2016) Vol. 21, Iss. 12, pp. 1450-1460
Open Access | Times Cited: 113
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot, Zoulika Kherrouche, Clotilde Descarpentries, et al.
JNCI Journal of the National Cancer Institute (2016) Vol. 109, Iss. 5
Open Access | Times Cited: 108
LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
Ling Liu, Wei Zeng, Mark A. Wortinger, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 23, pp. 6059-6070
Open Access | Times Cited: 102
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
Ali Hussein Mer, Yousef Mirzaei, Fatemeh Misamogooe, et al.
Drug Delivery and Translational Research (2024) Vol. 14, Iss. 11, pp. 2963-2988
Closed Access | Times Cited: 10
The Quorum Sensing Peptides PhrG, CSP and EDF Promote Angiogenesis and Invasion of Breast Cancer Cells In Vitro
Bart De Spiegeleer, Frederick Verbeke, Matthias D’Hondt, et al.
PLoS ONE (2015) Vol. 10, Iss. 3, pp. e0119471-e0119471
Open Access | Times Cited: 88
Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells
Peter V. Usatyuk, Panfeng Fu, Vijay Mohan, et al.
Journal of Biological Chemistry (2014) Vol. 289, Iss. 19, pp. 13476-13491
Open Access | Times Cited: 79
Novel therapeutic targets in non-small cell lung cancer
Muhammad Alamgeer, Vinod Ganju, D. Neil Watkins
Current Opinion in Pharmacology (2013) Vol. 13, Iss. 3, pp. 394-401
Closed Access | Times Cited: 78
Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
Ki Hyun Kim, Hyori Kim
Experimental & Molecular Medicine (2017) Vol. 49, Iss. 3, pp. e307-e307
Open Access | Times Cited: 74
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib
Yubo Wang, Li Li, Rui Han, et al.
Lung Cancer (2018) Vol. 118, pp. 105-110
Open Access | Times Cited: 63
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Seung Yeon Oh, You Won Lee, Eun Ji Lee, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 221-232
Open Access | Times Cited: 34
Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence
Radka Michalková, Ladislav Mirossay, Martin Kello, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10354-10354
Open Access | Times Cited: 18
The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
Benjamin D. Ferguson, Ren Liu, Cleo E. Rolle, et al.
PLoS ONE (2013) Vol. 8, Iss. 7, pp. e67668-e67668
Open Access | Times Cited: 66
Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wenjuan Wu, Bi Chen, Kelly M. Credille, et al.
Clinical Cancer Research (2013) Vol. 19, Iss. 20, pp. 5699-5710
Open Access | Times Cited: 62
Page 1 - Next Page

Scroll to top